Voor de beste ervaring schakelt u JavaScript in en gebruikt u een moderne browser!
Je gebruikt een niet-ondersteunde browser. Deze site kan er anders uitzien dan je verwacht.
What could the EU’s revision of its pharmaceutical legislation mean for access to novel medicines in the EU and for candidate countries? Katrina Perehudoff, from the Law Centre for Health and Life, was an expert invited to speak to this question at the Policy Dialogue with 10 countries in the Central European Initiative (CEI), organised by the WHO European Regional Office, CEI-Executive Secretariat, and the European Observatory on Health Systems and Policies.

The Policy Dialogue was hosted in Trieste on April 18-19, 2024 by the WHO European Regional Office, the Central European Initiative, and the European Observatory on Health Systems and Policies. It sought to strengthen pharmaceutical and health product systems by addressing quality assurance and regulatory oversight, shortages,  access to innovative medicines, and financial hardship.

Katrina’s contribution, based on her ongoing research exploring the EU’s role in global access to medicine, discussed the implications of the EU’s revised pharmaceutical

legislation (specifically data and market exclusivity rules, milestone prizes, and voluntary joint procurement) for the pricing of pharmaceuticals. Katrina’s participation was supported in part by a Veni talent grant from the Netherlands Organisation of Scientific Research and the Amsterdam University Funds.

Dr. S.K. (Katrina) Perehudoff

Faculteit der Rechtsgeleerdheid

Gezondheidsrecht